<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>A.P. Pharma Inc. News Release</title><link>http://phx.corporate-ir.net/Phoenix.zhtml?c=115565&amp;p=irol-news</link><description>A Collection of A.P. Pharma Inc. News Release</description><language>en-us</language><category>Uncategorized</category><lastBuildDate>Wed, 19 Jun 2013 02:36:29 GMT</lastBuildDate><item><title>A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1818139</link><description><![CDATA[REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 10, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for first quarter ended March 31, 2013 and highlighted recent corporate progress. 
Financial Results and Operational Highlights 
On May 2, 2013, the Company announced that the A.P. Pharma Board of Directors had appointed a new management team to lead the Company. This team includes Barry D. Quart, Pharm.D., who joined the Company as Chief Executive Officer, Robert Rosen, who joined A.P. Pharma in October 2012 as Senior Vice President and Chief Commercial Officer and was promoted to the role of President on May 1st and Steve Davis wh...]]></description><category>Uncategorized</category><guid isPermaLink="false">1818139_NEWS</guid><pubDate>Fri, 10 May 2013 12:00:00 GMT</pubDate></item><item><title>A.P. Pharma Appoints New Management Team</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1814279</link><description><![CDATA[- Barry D. Quart, Pharm.D. Appointed Chief Executive Officer - 
- Robert Rosen Appointed President - 
- Steve Davis Appointed Chief Operating Officer - 
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 2, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that its Board of Directors has appointed a new management team to lead the Company. Effective today, Barry D. Quart, Pharm.D. will join the Company as Chief Executive Officer, Robert Rosen, who joined A.P. Pharma in October 2012 as Senior Vice President and Chief Commercial Officer, will be promoted to the role of President, and Steve Davis will join the Company as Executive Vice President and Chie...]]></description><category>Uncategorized</category><guid isPermaLink="false">1814279_NEWS</guid><pubDate>Thu, 02 May 2013 12:00:00 GMT</pubDate></item><item><title>A.P. Pharma Receives FDA Complete Response Letter for APF530</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1801306</link><description><![CDATA[- Company Revises Projected Launch Timing from 2H 2013 to 1H 2014 -
    

      - Conference Call to Be Held at 8:30 a.m. Eastern Time -
    

    
    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 28, 2013--
      A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company,
      today announced that it has received a Complete Response Letter (CRL)
      from the U.S. Food and Drug Administration (FDA) regarding its New Drug
      Application (NDA) for its lead product candidate, APF530, for the
      prevention of chemotherapy-induced nausea and vomiting (CINV). The CRL
      describes the following issues that must be addressed.
    

      
        With respect ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1801306_NEWS</guid><pubDate>Thu, 28 Mar 2013 11:01:00 GMT</pubDate></item><item><title>A.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate Progress</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1791336</link><description><![CDATA[    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2013--
      A.P.
      Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company,
      today reported fourth quarter and full year 2012 financial results and
      highlighted recent corporate progress.
    

      “We achieved several critical objectives in 2012, highlighted by the
      resubmission of our New Drug Application for APF530 to FDA in September.
      Additionally, we have made a number of key appointments to the
      management team as we prepare for commercialization of APF530,” said
      John B. Whelan, A.P. Pharma’s President and Chief Executive Officer.
    

      Recent Accomplishments
    
...]]></description><category>Uncategorized</category><guid isPermaLink="false">1791336_NEWS</guid><pubDate>Fri, 01 Mar 2013 13:00:00 GMT</pubDate></item><item><title>A.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1790461</link><description><![CDATA[REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 28, 2013-- A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Jesse Hollingsworth as vice president of sales. 
“Jesse brings over a decade of highly relevant oncology sales experience, including a significant amount of knowledge working with group purchasing organizations,” said Robert Rosen, A.P. Pharma’s chief commercial officer. “Over the past several months, A.P. Pharma has been focused on recruiting key additions to our management team, and Jesse’s experience in oncology sales will provide insights into the sales program for our lead product candidate, APF530, which is being developed for the prevention of acute- and delayed-o...]]></description><category>Uncategorized</category><guid isPermaLink="false">1790461_NEWS</guid><pubDate>Thu, 28 Feb 2013 13:00:00 GMT</pubDate></item><item><title>A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1767682</link><description><![CDATA[– Joel Schaedler named as Vice President of Market Access – 
– Daniel Martin named Vice President of Marketing – 
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 17, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Joel Schaedler as vice president of market access and Daniel Martin as vice president of marketing. Mr. Schaedler will be responsible for the Company’s market access programs for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved. Mr. Martin will lead the marketing efforts for APF530. 
“The strategic expansion of our executive team is critical as we...]]></description><category>Uncategorized</category><guid isPermaLink="false">1767682_NEWS</guid><pubDate>Mon, 17 Dec 2012 13:01:00 GMT</pubDate></item><item><title>A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1766949</link><description><![CDATA[REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 13, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Mark S. Gelder, M.D. as senior vice president and chief medical officer. The addition of Dr. Gelder to A.P. Pharma’s executive team represents the Company’s continued efforts related to pre-commercialization activities for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved. 
“Mark will play a crucial role as A.P. Pharma’s chief medical officer as the organization continues to prepare for the potential commercialization of APF530,” said John B. Whelan, A.P. Pharma...]]></description><category>Uncategorized</category><guid isPermaLink="false">1766949_NEWS</guid><pubDate>Thu, 13 Dec 2012 13:01:00 GMT</pubDate></item><item><title>A.P. Pharma Announces Third Quarter 2012 Financial Results and Highlights Recent Corporate Progress</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1754010</link><description><![CDATA[REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended September 30, 2012 and highlighted recent corporate progress. 
"A.P. Pharma's accomplishments over the quarter have put us in a strong position as we approach a new era for the organization and begin preparing for commercialization of APF530," said John B. Whelan, A.P. Pharma's president and chief executive officer. "We successfully completed the resubmission of our New Drug Application for APF530 and secured the financing necessary to fund our operations through the anticipated APF530 product launch in 2013. In ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1754010_NEWS</guid><pubDate>Mon, 05 Nov 2012 13:01:00 GMT</pubDate></item><item><title>A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1747039</link><description><![CDATA[REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 18, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Robert Rosen as senior vice president and chief commercial officer. Mr. Rosen will oversee all of A.P. Pharma’s commercial activities, including the commercial launch of APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved. Mr. Rosen also will continue to serve as a director of the Company. 
“We are delighted to bring Robert on to the A.P. Pharma management team,” stated John Whelan, president and chief executive officer. “Robert’s deep and extensive experience com...]]></description><category>Uncategorized</category><guid isPermaLink="false">1747039_NEWS</guid><pubDate>Thu, 18 Oct 2012 12:01:00 GMT</pubDate></item><item><title>A.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application Resubmission</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=115565&amp;p=RssLanding&amp;cat=news&amp;id=1745698</link><description><![CDATA[    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 16, 2012--
      A.P.
      Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company,
      announced today that the U.S. Food and Drug Administration (FDA) has
      accepted the Company’s resubmission of its New Drug Application (NDA)
      for APF530. The FDA has set a Prescription Drug User Fee Act (PDUFA)
      action date of March 27, 2013. APF530 is a long-acting formulation of
      granisetron and is being developed for the prevention of acute- and
      delayed-onset chemotherapy-induced nausea and vomiting (CINV).
    

      "The acceptance of our New Drug Application for APF530 represents an
      important step t...]]></description><category>Uncategorized</category><guid isPermaLink="false">1745698_NEWS</guid><pubDate>Tue, 16 Oct 2012 12:01:00 GMT</pubDate></item></channel></rss>